AI Article Synopsis
- Comprehensive genomic profiling (CGP) using next-generation sequencing is enhancing precision medicine for advanced cancers, especially pancreatic cancers.
- Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) and biopsy (EUS-FNB) are critical techniques for diagnosing abdominal masses but face challenges with CGP success rates.
- The article reviews the evolution from EUS-FNA to EUS-FNB, compares their effectiveness, and addresses current challenges in genomic analysis for hepatobiliary-pancreatic cancers.
Article Abstract
Comprehensive genomic profiling based on next-generation sequencing has recently been used to provide precision medicine for various advanced cancers. Endoscopic ultrasound (EUS)-guided fine-needle aspiration (EUS-FNA) and EUS-guided fine-needle biopsy (EUS-FNB) play essential roles in the diagnosis of abdominal masses, mainly pancreatic cancers. In recent years, CGP analysis using EUS-FNA/FNB specimens for hepatobiliary-pancreatic cancers has increased; however, the success rate of CGP analysis is not clinically satisfactory, and many issues need to be resolved to improve the success rate of CGP analysis. In this article, we review the transition from EUS-FNA to FNB, compare each test, and discuss the current status and issues in genomic analysis of hepatobiliary-pancreatic cancers using EUS-FNA/FNB specimens.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10590314 | PMC |
| http://dx.doi.org/10.1007/s00535-023-02037-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!